{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000085","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.641169+00:00","generated_at":"2026-06-12T19:44:57.822495+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer Q2 revenues $12.7B (-54% YoY); narrows FY revenue guidance to $67-70B","bullets":["Q2 reported diluted EPS $0.41 (-77% YoY); adjusted diluted EPS $0.67 (-67% YoY).","Comirnaty and Paxlovid combined revenue $1.6B; ex-COVID revenue grew 5% operationally.","Narrowed FY2023 revenue guidance to $67-70B (previously $67-71B); maintained adjusted EPS guidance $3.25-3.45.","Non-COVID operational growth expectation reduced to 6-8% from 7-9% due to label, ACIP recommendation, tornado damage.","Closed $31B debt offering to partly fund Seagen acquisition; transaction expected late 2023/early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000085","json":"https://secwatch.observer/filing/0000078003-23-000085.json","markdown":"https://secwatch.observer/filing/0000078003-23-000085.md","text":"https://secwatch.observer/filing/0000078003-23-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/0000078003-23-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/pfe-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T19:44:57.822495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52600413a25c45b68a893a0ff9b1249bb6248f9c","claim":"PFIZER INC reported the second quarter of 2023 results: revenue $12,734, net income $2,327, EPS $0.41. Guidance reaffirmed.","evidence_excerpt":"of 2023 and 2022 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Second-Quarter Six Months 2023 2022 Change 2023 2022 Change Revenues $ 12,734 $ 27,742 (54%) $ 31,015 $ 53,402 (42%) Reported Net Income (2) 2,327 9,906 (77%) 7,870 17,769 (56%) Reported Diluted EPS (2) 0.41 1.73 (77%) 1.38 3.10 (56%) Adjusted (3) Income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/0000078003-23-000085-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$12,734"},{"label":"Net income","value":"$2,327"},{"label":"EPS","value":"$0.41"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}